FR2897513A1 - Composition, useful as food complement, to prevent acne and for photoprotection, comprises herbal extract containing epigallocatechin gallate, humulone and zinc - Google Patents
Composition, useful as food complement, to prevent acne and for photoprotection, comprises herbal extract containing epigallocatechin gallate, humulone and zinc Download PDFInfo
- Publication number
- FR2897513A1 FR2897513A1 FR0650573A FR0650573A FR2897513A1 FR 2897513 A1 FR2897513 A1 FR 2897513A1 FR 0650573 A FR0650573 A FR 0650573A FR 0650573 A FR0650573 A FR 0650573A FR 2897513 A1 FR2897513 A1 FR 2897513A1
- Authority
- FR
- France
- Prior art keywords
- composition according
- humulone
- composition
- zinc
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 206010000496 acne Diseases 0.000 title claims abstract description 20
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 19
- 239000011701 zinc Substances 0.000 title claims abstract description 18
- 229910052725 zinc Inorganic materials 0.000 title claims abstract description 18
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 title claims abstract description 17
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 title claims abstract description 17
- 229940030275 epigallocatechin gallate Drugs 0.000 title claims abstract description 17
- RMFGNMMNUZWCRZ-UHFFFAOYSA-N Humulone Natural products CC(C)CC(=O)C1=C(O)C(O)(CC=C(C)C)C(O)=C(CC=C(C)C)C1=O RMFGNMMNUZWCRZ-UHFFFAOYSA-N 0.000 title claims abstract description 15
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 title claims abstract description 15
- VMSLCPKYRPDHLN-NRFANRHFSA-N humulone Chemical compound CC(C)CC(=O)C1=C(O)C(CC=C(C)C)=C(O)[C@@](O)(CC=C(C)C)C1=O VMSLCPKYRPDHLN-NRFANRHFSA-N 0.000 title claims abstract description 15
- 230000003711 photoprotective effect Effects 0.000 title claims abstract description 10
- 230000000295 complement effect Effects 0.000 title abstract description 3
- 235000013305 food Nutrition 0.000 title abstract description 3
- 239000012676 herbal extract Substances 0.000 title abstract 2
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 claims description 16
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 16
- 239000000419 plant extract Substances 0.000 claims description 14
- 235000021324 borage oil Nutrition 0.000 claims description 10
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 9
- 239000011648 beta-carotene Substances 0.000 claims description 9
- 235000013734 beta-carotene Nutrition 0.000 claims description 9
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 9
- 229960002747 betacarotene Drugs 0.000 claims description 9
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 9
- 229940087168 alpha tocopherol Drugs 0.000 claims description 8
- 239000011795 alpha-carotene Substances 0.000 claims description 8
- 235000003903 alpha-carotene Nutrition 0.000 claims description 8
- ANVAOWXLWRTKGA-HLLMEWEMSA-N alpha-carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)\C)(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C ANVAOWXLWRTKGA-HLLMEWEMSA-N 0.000 claims description 8
- 235000010382 gamma-tocopherol Nutrition 0.000 claims description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 8
- 229960000984 tocofersolan Drugs 0.000 claims description 8
- 239000002076 α-tocopherol Substances 0.000 claims description 8
- 235000004835 α-tocopherol Nutrition 0.000 claims description 8
- 239000002478 γ-tocopherol Substances 0.000 claims description 8
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 claims description 8
- 235000015872 dietary supplement Nutrition 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 229930003799 tocopherol Natural products 0.000 claims description 6
- 239000011732 tocopherol Substances 0.000 claims description 6
- 235000019149 tocopherols Nutrition 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 235000021466 carotenoid Nutrition 0.000 claims description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- 150000001747 carotenoids Chemical class 0.000 claims description 3
- 235000020688 green tea extract Nutrition 0.000 claims description 3
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 claims description 3
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims description 2
- 241000251468 Actinopterygii Species 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- SXQXMCWCWVCFPC-UHFFFAOYSA-N aluminum;potassium;dioxido(oxo)silane Chemical compound [Al+3].[K+].[O-][Si]([O-])=O.[O-][Si]([O-])=O SXQXMCWCWVCFPC-UHFFFAOYSA-N 0.000 claims description 2
- 235000013871 bee wax Nutrition 0.000 claims description 2
- 239000012166 beeswax Substances 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 229940094952 green tea extract Drugs 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000008347 soybean phospholipid Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims 1
- 239000013066 combination product Substances 0.000 claims 1
- 229940127555 combination product Drugs 0.000 claims 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 239000010936 titanium Substances 0.000 claims 1
- 229910052719 titanium Inorganic materials 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 2
- 239000002677 5-alpha reductase inhibitor Substances 0.000 abstract 1
- 229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 abstract 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 235000016804 zinc Nutrition 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 7
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 5
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 235000009569 green tea Nutrition 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 235000008694 Humulus lupulus Nutrition 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 229940030486 androgens Drugs 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 150000002736 metal compounds Chemical class 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- 241001072256 Boraginaceae Species 0.000 description 1
- 235000007689 Borago officinalis Nutrition 0.000 description 1
- 102000015280 CCAAT-Enhancer-Binding Protein-beta Human genes 0.000 description 1
- 108010064535 CCAAT-Enhancer-Binding Protein-beta Proteins 0.000 description 1
- 208000035484 Cellulite Diseases 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 241000347881 Kadua laxiflora Species 0.000 description 1
- 206010049752 Peau d'orange Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- 229940098330 gamma linoleic acid Drugs 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000011268 leukocyte chemotaxis Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
Description
L'invention a pour objet une composition pour complément alimentaire àThe subject of the invention is a composition for a dietary supplement to
administration orale, destinée à la prévention de l'acné et à la photoprotection. oral administration, for the prevention of acne and photoprotection.
L'acné vulgaire (acne vulgaris) communément appelée acné est un trouble affectant 80% des jeunes gens âgés de 12 à 18 ans. Toutefois, il est important de prendre en compte une prévalence relativement élevée chez la femme adulte âgée de 25 à 40 ans. Ainsi la prévalence totale de l'acné chez les femmes françaises atteint 41 %. io Les quatre principaux facteurs étiologiques de l'acné vulgaire sont la séborrhée, la comédogenèse (comprenant la stimulation de la sécrétion sébacée et la rétention avec une hyperkératose de l'ostium folliculaire), la colonisation du canal par Propionibacterium acnes (germe anaérobie, Gram positif, possédant une action inflammatoire) et la mise en oeuvre de la réaction 15 inflammatoire proprement dite. De nombreux produits sont mis à la disposition du consommateur tels que des produits cosmétiques, des médicaments et plus récemment des compléments alimentaires. Les personnes souhaitant prévenir l'acné, se protéger du soleil et préparer leur peau au bronzage doivent souvent utiliser 20 différents produits, ce qui n'est ni pratique d'un point de vue administration ni sûr car ces produits n'ont pas pour but d'être associés. De plus les traitements anti-acnéiques sont très souvent photosensibilisants. Acne vulgaris (acne vulgaris) commonly known as acne is a disorder affecting 80% of young people aged 12 to 18 years. However, it is important to consider a relatively high prevalence in adult women aged 25 to 40 years. Thus the total prevalence of acne in French women reaches 41%. The four main etiological factors of acne vulgaris are seborrhea, comedogenesis (including stimulation of sebaceous secretion and retention with hyperkeratosis of the follicular ostium), colonization of the duct by Propionibacterium acnes (anaerobic germ, Gram). positive, having an inflammatory action) and the implementation of the inflammatory reaction itself. Many products are available to the consumer such as cosmetics, medicines and more recently dietary supplements. People who want to prevent acne, protect themselves from the sun and prepare their skin for tanning must often use 20 different products, which is not practical from an administration point of view or safe because these products are not intended to be associated. In addition, anti-acne treatments are very often photosensitizers.
L'état de la technique peut être défini notamment par : 25 - le brevet américain numéro US 2004/0253332 qui décrit une composition à application topique pour réduire les problèmes de peau dus au vieillissement induits par les rayons UV. Cette composition associe des tannins, hydrolysables de faible poids moléculaire, à au moins un élément parmi des anti-acnéiques, des agents anti-cellulites, des agents antimicrobiens, 30 antifungiques, des vitamines, des anti-inflammatoires, des agents bronzants et des écrans solaires. Cette composition ne permet pas de résoudre le problème particulier posé par la prévention de l'acné. - le brevet WO 2005/041916 propose une composition orale comprenant une première composition contenant un extrait de thé vert et de la vitamine C et éventuellement au moins un composé métallique choisi parmi le fer, le cuivre, le zinc, le chrome et un mélange de ceux-ci, et une seconde composition contenant au moins un composé métallique choisi parmi le fer, le cuivre, le zinc, le chrome et un mélange de ceux-ci. Cette composition est destinée à traiter les affections et/ou déséquilibres de la peau, des phanères et/ou traiter la surcharge pondérale. Cette invention n'a pas d'action photoprotectrice, de plus elle implique l'administration de deux compositions, ce qui ne résout pas le io problème posé par l'invention. The state of the art can be defined in particular by: US Patent Number US 2004/0253332 which discloses a topically applied composition for reducing skin problems due to aging induced by UV rays. This composition combines hydrolyzable, low molecular weight tannins with at least one of anti-acne agents, anti-cellulite agents, antimicrobial agents, antifungal agents, vitamins, anti-inflammatories, bronzers and screens. solar. This composition does not solve the particular problem posed by the prevention of acne. the patent WO 2005/041916 proposes an oral composition comprising a first composition containing a green tea extract and vitamin C and optionally at least one metal compound chosen from iron, copper, zinc, chromium and a mixture of these, and a second composition containing at least one metal compound selected from iron, copper, zinc, chromium and a mixture thereof. This composition is intended to treat disorders and / or imbalances of the skin, superficial body growths and / or overweight. This invention has no photoprotective action, moreover it involves the administration of two compositions, which does not solve the problem posed by the invention.
L'invention a pour objet une composition pour complément alimentaire à administration orale quotidienne, destinée à la prévention de l'acné et à la photoprotection, comprenant au moins un extrait végétal contenant de 15 l'épigallocatéchine gallate , un extrait végétal contenant de l'humulone et du zinc. La demanderesse a découvert de manière surprenante que l'épigallocatéchine gallate, l'humulone, le zinc, les caroténoïdes, les tocophérols et l'huile de bourrache ont des actions synergiques et que leur association dans 20 des compléments alimentaires permet d'exercer une action préventive sur l'acné ainsi qu'une photoprotection. Le zinc agit sur la composante inflammatoire de l'acné. Il agit par une inhibition de la chemotaxie des leucocytes polymorphonucléaires induite par une diminution de la concentration granulocytaire en zinc. De plus, il existe un 25 risque de déficience en zinc dans toute l'Europe. L'humulone contenue dans des extraits végétaux et en particulier dans l'extrait de houblon supprime l'induction de la cyclooxygénase-2 (COX-2) dépendante du TNF-alpha, bloque l'expression de la COX-2 régulée par le NF-kappa B et le NF-IL6 et inhibe l'activité catalytique de la COX-2. Ces différents 30 effets diminuent ainsi l'action angiogénique de la COX-2 ce qui réduit l'inflammation. Or une inflammation excessive, dans les tissus en voie de guérison, conduit à l'aggravation de l'état de la peau. The subject of the invention is a dietary supplement composition for daily oral administration intended for the prevention of acne and for photoprotection, comprising at least one plant extract containing epigallocatechin gallate, a plant extract containing humulone and zinc. The Applicant has surprisingly discovered that epigallocatechin gallate, humulone, zinc, carotenoids, tocopherols and borage oil have synergistic actions and that their combination in food supplements allows to exercise an action. prevention on acne as well as photoprotection. Zinc acts on the inflammatory component of acne. It acts by inhibition of polymorphonuclear leukocyte chemotaxis induced by a decrease in granulocyte concentration in zinc. In addition, there is a risk of zinc deficiency throughout Europe. The humulone contained in plant extracts and in particular in the hop extract suppresses the induction of TNF-alpha-dependent cyclooxygenase-2 (COX-2), blocks the expression of COX-2 regulated by NF -kappa B and NF-IL6 and inhibits the catalytic activity of COX-2. These different effects thus reduce the angiogenic action of COX-2 which reduces inflammation. However, excessive inflammation in healing tissues leads to worsening of the skin's condition.
L'épigallocatéchine gallate (EGCG) contenue dans des extraits végétaux et en particulier dans le thé vert, est un inhibiteur de l'enzyme stéroïde 5 alpharéductase de type I, présente au niveau des glandes sébacées et de la partie dermique de l'infundibulum pilo-sébacé. Cette inhibition limite la transformation de la testostérone en 5 alpha-dihydrotestostérone et autres androgènes. Or les androgènes sembleraient jouer un rôle dans le développement de l'acné ; une réduction du nombre de comédons a été observée lorsque le patient est sous thérapie anti-androgénique, par exemple au moyen de la prescription de contraceptifs par voie orale. De plus les extraits de thé vert et en particulier io I'EGCG, sont bactéricides sur les bactéries Gram positives se développant notamment au niveau des lésions acnéiques et ils sont dermoprotecteurs car ils possèdent des propriétés anti-oxydantes qui sont intéressantes pour réduire les dommages de la peau dus aux radicaux libres induits par le rayonnement ultra violet. 15 De même les tocophérols, possèdent un pouvoir antioxydant qui aide la peau à lutter contre les effets néfastes des radicaux libres et un effet anti-inflammatoire qui favorise la cicatrisation des lésions. Par ailleurs les caroténoïdes, sont décrits dans diverses recherches comme ayant une action sur la pigmentation de la peau et sur la 20 dermoprotection. Ainsi, ils sont d'utiles protecteurs solaires oraux et des hautes doses de bêta-carotène protègent contre la formation d'érythème induit par les rayons ultra-violets. Enfin l'huile de bourrache contient de nombreux acides gras essentiels, en particulier l'acide gamma-linoléique, permettant une amélioration de la 25 souplesse de l'épiderme et empêchant la déshydratation de la peau. L'épigallocatéchine gallate, l'humulone, et le zinc, selon la présente invention s'avèrent être des composés cosmétiquement acceptables non agressifs, non toxiques et une prise quotidienne permet de rester dans des conditions alimentaires et non thérapeutiques. 30 La présente invention a pour objet une composition destinée à un complément alimentaire à administration orale comprenant au moins : - un extrait végétal, en particulier de thé vert, contenant de l'épigallocatéchine gallate - un extrait végétal, en particulier de houblon, contenant de l'humulone - du zinc - des carotènoïdes, en particulier de l'alpha-carotène et du bêta-carotène - des tocophérols en particulier de l'alpha-tocophérol et du gamma- tocophérol - de l'huile de bourrache - des excipients La masse totale de la composition comprend : - de 5 à 15 mg d'épigallocatéchine gallate io - de 25 à 35 mg d'humulone - de 7,5 à 15 mg de zinc - de 1,2 à 2,4 mg d'alpha-carotène - de 2,5 à 5,0 mg de bêta-carotène - de 15,0 à 30 mg de gamma-tocophérol 15 - de 3,5 à 7 mg d'alpha-tocophérol - de 200 à 300mg d'huile de bourrache le complément étant constitué d'excipients Plus précisément la masse totale de la composition comprend : - 10 mg d'épigallocatéchine gallate 20 - 30 mg d'humulone - 15,0 mg de zinc - 2,4 mg d'alpha-carotène - 5,0 mg de bêta-carotène - 29,4 mg de gamma-tocophérol 25 - 6,9 mg d'alpha- tocophérol - 235 mg d'huile de bourrache le complément étant constitué d'excipients. The epigallocatechin gallate (EGCG) contained in plant extracts and in particular in green tea, is an inhibitor of the steroid enzyme type I, present in the sebaceous glands and the dermal part of the infundibulum pilo. -sebaceous. This inhibition limits the transformation of testosterone into 5 alpha-dihydrotestosterone and other androgens. But androgens seem to play a role in the development of acne; a reduction in the number of comedones has been observed when the patient is on anti-androgenic therapy, for example by means of the prescription of oral contraceptives. In addition, green tea extracts, and in particular EGCG, are bactericidal on gram-positive bacteria which develop in particular in acne lesions and are dermoprotective because they have antioxidant properties which are of interest for reducing the damage of the skin. skin due to free radicals induced by ultraviolet radiation. Likewise, tocopherols have an antioxidant power which helps the skin to fight against the harmful effects of free radicals and an anti-inflammatory effect which promotes the healing of lesions. Carotenoids, moreover, are described in various studies as having an effect on skin pigmentation and on dermoprotection. Thus, they are useful oral sun protectors and high doses of beta-carotene protect against the formation of erythema induced by ultraviolet rays. Finally, borage oil contains many essential fatty acids, in particular gamma-linoleic acid, which improves the suppleness of the epidermis and prevents dehydration of the skin. Epigallocatechin gallate, humulone, and zinc, according to the present invention prove to be cosmetically acceptable non-aggressive, non-toxic and a daily intake allows to remain in food and non-therapeutic conditions. The present invention relates to a composition for an oral food supplement comprising at least: - a plant extract, in particular of green tea, containing epigallocatechin gallate - a plant extract, in particular of hops, containing humulone - zinc - carotenoids, in particular alpha-carotene and beta-carotene - tocopherols, in particular alpha-tocopherol and gamma-tocopherol - borage oil - excipients total mass of the composition comprises: - from 5 to 15 mg of epigallocatechin gallate io - from 25 to 35 mg of humulone - from 7.5 to 15 mg of zinc - from 1.2 to 2.4 mg of alpha -carotene - 2.5 to 5.0 mg beta-carotene - 15.0 to 30 mg gamma-tocopherol 15 - 3.5 to 7 mg alpha-tocopherol - 200 to 300 mg oil borage the complement consisting of excipients More precisely the total mass of the composition comprises: - 10 mg of epigalloca tchine gallate 20 - 30 mg humulone - 15.0 mg zinc - 2.4 mg alpha-carotene - 5.0 mg beta-carotene - 29.4 mg gamma-tocopherol 25 - 6.9 mg of alpha-tocopherol - 235 mg of borage oil, the remainder consisting of excipients.
Dans un mode d'administration préféré la présente invention est administrée 30 oralement par capsule dont la composition galénique comprend : Des principes actifs : - 10 mg d'épigallocatéchine gallate mg d'humulone 5 10 - 15,0 mg de zinc - 2,4 mg d'alpha-carotène - 5,0 mg de bêta-carotène - 29,4 mg de gamma-tocophérol - 6,9 mg d'alpha-tocophérol -235 mg d'huile de bourrache et des excipients : - 18,68 mg de cire d'abeille - 10 mg de lécithine de soja - 137 mg de gélatine de poisson 63 mg de glycérine - 5,2 mg de silicate de potassium aluminum - 3,5 mg de dioxyde de titane - 0,5 mg d'oxyde de fer rouge 15 La présente invention a pour objet l'utilisation d'une composition caractérisée par le fait qu'elle implique une administration orale d'une combinaison comprenant au moins : - un extrait végétal, en particulier de thé vert, contenant de 20 l'épigallocatéchine gallate - un extrait végétal, en particulier de houblon, contenant des humulones - du zinc - des caroténoïdes, en particulier de l'alpha-carotène et du bêta-carotène - des tocophérols en particulier de l'alpha-tocophérol et du gamma-25 tocophérol - de l'huile de bourrache - des excipients In a preferred mode of administration the present invention is administered orally per capsule whose pharmaceutical composition comprises: Active ingredients: - 10 mg of epigallocatechin gallate mg of humulone 10 - 15.0 mg of zinc - 2,4 mg of alpha-carotene - 5.0 mg of beta-carotene - 29.4 mg of gamma-tocopherol - 6.9 mg of alpha-tocopherol -235 mg of borage oil and excipients: - 18.68 mg of beeswax - 10 mg of soy lecithin - 137 mg of fish gelatin 63 mg of glycerine - 5.2 mg of aluminum potassium silicate - 3.5 mg of titanium dioxide - 0.5 mg of The present invention relates to the use of a composition characterized by the fact that it involves an oral administration of a combination comprising at least: a plant extract, in particular of green tea, containing Epigallocatechin gallate - a plant extract, in particular of hops, containing humulones - zinc - carotins enoids, in particular alpha-carotene and beta-carotene - tocopherols, in particular alpha-tocopherol and gamma-tocopherol - borage oil - excipients
La présente invention a pour objet l'utilisation d'une composition à double 30 action : prévention de l'acné et photoprotection. La présente invention a pour objet l'utilisation d'une composition impliquant l'administration orale d'une dose journalière. The present invention relates to the use of a dual action composition: acne prevention and photoprotection. The present invention relates to the use of a composition involving the oral administration of a daily dose.
La présente invention a pour objet une composition destinée à un complément alimentaire à administration orale à double d'action : prévention de l'acné et photoprotection, se présentant sous forme de capsules, gélules, comprimés, granules, poudres ou solutions buvables.5 The subject of the present invention is a composition intended for a double-action oral nutritional supplement: prevention of acne and photoprotection, in the form of capsules, capsules, tablets, granules, powders or drinkable solutions.
Claims (9)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0650573A FR2897513B1 (en) | 2006-02-20 | 2006-02-20 | COMPOSITION FOR ORAL ADMINISTRATION SUPPLEMENT FOR ACNE PREVENTION AND PHOTOPROTECTION |
MC2531A MC200093A1 (en) | 2006-02-20 | 2007-02-14 | Oral dietary supplement composition for the prevention of acne and photoprotection |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0650573A FR2897513B1 (en) | 2006-02-20 | 2006-02-20 | COMPOSITION FOR ORAL ADMINISTRATION SUPPLEMENT FOR ACNE PREVENTION AND PHOTOPROTECTION |
Publications (2)
Publication Number | Publication Date |
---|---|
FR2897513A1 true FR2897513A1 (en) | 2007-08-24 |
FR2897513B1 FR2897513B1 (en) | 2010-08-20 |
Family
ID=37054535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR0650573A Active FR2897513B1 (en) | 2006-02-20 | 2006-02-20 | COMPOSITION FOR ORAL ADMINISTRATION SUPPLEMENT FOR ACNE PREVENTION AND PHOTOPROTECTION |
Country Status (2)
Country | Link |
---|---|
FR (1) | FR2897513B1 (en) |
MC (1) | MC200093A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009127073A1 (en) * | 2008-04-18 | 2009-10-22 | Gen Sod2 Foundation | Cosmetic preparation tailored to an individual and method for the production thereof |
WO2010025335A2 (en) * | 2008-08-29 | 2010-03-04 | Dr Pepper/Seven Up, Inc. | Functional consumable compositions for promoting skin health and methods for using the same |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5962517A (en) * | 1997-01-31 | 1999-10-05 | Murad; Howard | Pharmaceutical compositions and methods for treating acne |
US6255290B1 (en) * | 1997-11-04 | 2001-07-03 | Pro-Neuron, Inc. | Antimutagenic compositions for treatment and prevention of photodamage to skin |
US20030072777A1 (en) * | 2001-10-05 | 2003-04-17 | Maes Daniel H. | Combinatorial anti-acne compositions |
WO2004023897A1 (en) * | 2002-09-12 | 2004-03-25 | Marc Schwaller | Composition containing in combination at least one gourd oil and at least one borage oil, use thereof as medicine, as dermatological or dermato-cosmetic agent |
US20040137096A1 (en) * | 2003-01-09 | 2004-07-15 | Kuhrts Eric H. | Anti-inflammatory cyclooxygenase-2 selective inhibitors |
WO2005041916A1 (en) * | 2003-11-03 | 2005-05-12 | Baudry Jacquet | Oral composition including a first composition (a) and a second composition (b) for use as a mixture for separate or consecutive use in the cosmetic treatment of the human body |
-
2006
- 2006-02-20 FR FR0650573A patent/FR2897513B1/en active Active
-
2007
- 2007-02-14 MC MC2531A patent/MC200093A1/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5962517A (en) * | 1997-01-31 | 1999-10-05 | Murad; Howard | Pharmaceutical compositions and methods for treating acne |
US6255290B1 (en) * | 1997-11-04 | 2001-07-03 | Pro-Neuron, Inc. | Antimutagenic compositions for treatment and prevention of photodamage to skin |
US20030072777A1 (en) * | 2001-10-05 | 2003-04-17 | Maes Daniel H. | Combinatorial anti-acne compositions |
WO2004023897A1 (en) * | 2002-09-12 | 2004-03-25 | Marc Schwaller | Composition containing in combination at least one gourd oil and at least one borage oil, use thereof as medicine, as dermatological or dermato-cosmetic agent |
US20040137096A1 (en) * | 2003-01-09 | 2004-07-15 | Kuhrts Eric H. | Anti-inflammatory cyclooxygenase-2 selective inhibitors |
WO2005041916A1 (en) * | 2003-11-03 | 2005-05-12 | Baudry Jacquet | Oral composition including a first composition (a) and a second composition (b) for use as a mixture for separate or consecutive use in the cosmetic treatment of the human body |
Non-Patent Citations (1)
Title |
---|
LIAO S ET AL: "SELECTIVE INHIBITION OF STEROID 5ALPHA-REDUCTASE ISOZYMES BY EPICATECHIN-3-GALLATE AND EPIGALLOCATECHIN-3-GALLATE", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 214, no. 3, 25 February 1995 (1995-02-25), pages 833 - 838, XP002921422, ISSN: 0006-291X * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009127073A1 (en) * | 2008-04-18 | 2009-10-22 | Gen Sod2 Foundation | Cosmetic preparation tailored to an individual and method for the production thereof |
WO2010025335A2 (en) * | 2008-08-29 | 2010-03-04 | Dr Pepper/Seven Up, Inc. | Functional consumable compositions for promoting skin health and methods for using the same |
WO2010025335A3 (en) * | 2008-08-29 | 2010-05-20 | Dr Pepper/Seven Up, Inc. | Functional consumable compositions for promoting skin health |
Also Published As
Publication number | Publication date |
---|---|
MC200093A1 (en) | 2007-10-10 |
FR2897513B1 (en) | 2010-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pundir et al. | Ethnomedicinal uses, phytochemistry and dermatological effects of Hippophae rhamnoides L.: A review | |
KR101713357B1 (en) | Cosmetic composition for the treatment of acne comprising a peptide extract of schizandra | |
EP2654765B1 (en) | Extract of the aerial parts of maca rich in polyphenol and composition comprising the extract | |
CN102123705A (en) | Dermatological pharmaceutical composition for the treatment of skin inflammation diseases, such as dermatitis, atopic dermatitis, vitiligo, alopecia areata, acne, psoriasis, pruritus or combinations of same | |
JP5084512B2 (en) | Antioxidant dietary supplement compositions and methods for maintaining healthy skin | |
US20060292255A1 (en) | Pharmaceutical and therapeutic compositions derived from Garcinia mangostana L plant | |
WO2003084553A1 (en) | Topical pharmaceutical compositions comprising proanthocyanidins for the treatment of dermatitis | |
WO2006015135A2 (en) | Methods of managing the redness associated with a dermatological condition | |
WO2007002666A2 (en) | Pharmaceutical and therapeutic compostions derived from garcinia mangostana l plant | |
JP2004506657A (en) | Bioavailable compositions of natural and synthetic HCA | |
TW201028145A (en) | Composition comprising hemp oil for treating topical diseases | |
KR20200095476A (en) | Dietary composition containing a plant-based fatty acid source | |
CA2531186C (en) | Use of an antioxidant in a dermatological and/or cosmetic composition | |
US20220183951A1 (en) | Skin treatment methods and compositions with retinoid and delivery systems thereof | |
US8142821B2 (en) | Xanthohumol-enriched hop extract | |
KR20120021353A (en) | Composition of external application for using bamboo sprout | |
FR2897513A1 (en) | Composition, useful as food complement, to prevent acne and for photoprotection, comprises herbal extract containing epigallocatechin gallate, humulone and zinc | |
KR20070000675A (en) | Composition containing mung bean extract, bletillae tuber extract and black cohosh extract and use thereof | |
WO2015057110A2 (en) | Cosmetic for rapid skin regeneration | |
US20050106263A1 (en) | Green tea, multivitamin, mineral and herb based hair and male facial skin formulas | |
JP2017510630A (en) | Compositions and methods for inhibiting triglyceride synthesis by synergistic combination of botanical formulations | |
KR101314680B1 (en) | Cosmetic compositions containing bokbunja pouder | |
WO2017009870A1 (en) | A topical formulation for chronic skin and hair disease | |
JP2004307372A (en) | External preparation for acne, use of plum extract and germicidal and antibacterial agent | |
WO2022167652A1 (en) | Supplement for arthritis and psoriasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PLFP | Fee payment |
Year of fee payment: 11 |
|
PLFP | Fee payment |
Year of fee payment: 12 |
|
PLFP | Fee payment |
Year of fee payment: 13 |
|
PLFP | Fee payment |
Year of fee payment: 15 |
|
PLFP | Fee payment |
Year of fee payment: 16 |
|
PLFP | Fee payment |
Year of fee payment: 17 |
|
PLFP | Fee payment |
Year of fee payment: 18 |
|
PLFP | Fee payment |
Year of fee payment: 19 |